Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6936MR)

This product GTTS-WQ6936MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6936MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1624MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ10719MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ5956MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ1984MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ7956MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ7413MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ1838MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ8815MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW